Peptide record

TPDB13160

Antibacterial Toxicity standard
19 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB13160
Antibacterial Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia
standard
No
A 19-aa standard natural multi-activity (Antibacterial and Toxicity) peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.
Sequence
ALWKSILKNVGKAAGKAVL
Physicochemical Analysis
C92H159N25O22
RDCEQHMFPTY
AK
1967.43
11.00
4
0
11
+4
0.15
0.521
133.68
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
5500
279.55
2
Residue Composition
number
4
A
0
R
1
N
0
D
0
C
0
E
0
Q
2
G
0
H
1
I
3
L
4
K
0
M
0
F
0
P
1
S
0
T
1
W
0
Y
2
V
Amino Acid Distribution
A: 4 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 1 L: 3 K: 4 M: 0 F: 0 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 2
Chemical Descriptors
19
C92H159N25O22
1967.43
11.00
+4
0.15
0.521
Evidence Records 5 records
Evidence 1 Activity

Activity

0% Hemolysis
Toxicity
64 µM
Hemolytic Cytotoxic
0% Hemolysis | 64 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Design of N-Terminal Derivatives from a Novel Dermaseptin Exhibiting Broad-Spectrum Antimicrobial Activity against Isolates from Cystic Fibrosis Patients | Biomolecules | 2019
Evidence 2 Activity

Activity

5% Hemolysis
Toxicity
128 µM
Hemolytic Cytotoxic
5% Hemolysis | 128 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Design of N-Terminal Derivatives from a Novel Dermaseptin Exhibiting Broad-Spectrum Antimicrobial Activity against Isolates from Cystic Fibrosis Patients | Biomolecules | 2019
Evidence 3 Activity

Activity

10% Hemolysis
Toxicity
256 µM
Hemolytic Cytotoxic
10% Hemolysis | 256 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Design of N-Terminal Derivatives from a Novel Dermaseptin Exhibiting Broad-Spectrum Antimicrobial Activity against Isolates from Cystic Fibrosis Patients | Biomolecules | 2019
Evidence 4 Activity

Activity

38% Killing
Toxicity
125 µg/mL
Cytotoxic
38% Killing | 125 | µg/mL | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Systematic comparison of activity and mechanism of antimicrobial peptides against nosocomial pathogens. | Eur J Med Chem | 2022
Evidence 5 Activity

Activity

83% Killing
Toxicity
250 µg/mL
Cytotoxic
83% Killing | 250 | µg/mL | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Systematic comparison of activity and mechanism of antimicrobial peptides against nosocomial pathogens. | Eur J Med Chem | 2022